Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Nucleic Acids Res ; 35(5): e34, 2007.
Article in English | MEDLINE | ID: mdl-17267408

ABSTRACT

Using the relative expression levels of two SNP alleles of a gene in the same sample is an effective approach for identifying cis-acting regulatory SNPs (rSNPs). In the current study, we established a process for systematic screening for cis-acting rSNPs using experimental detection of AI as an initial approach. We selected 160 expressed candidate genes that are involved in cancer and anticancer drug resistance for analysis of AI in a panel of cell lines that represent different types of cancers and have been well characterized for their response patterns against anticancer drugs. Of these genes, 60 contained heterozygous SNPs in their coding regions, and 41 of the genes displayed imbalanced expression of the two cSNP alleles. Genes that displayed AI were subjected to bioinformatics-assisted identification of rSNPs that alter the strength of transcription factor binding. rSNPs in 15 genes were subjected to electrophoretic mobility shift assay, and in eight of these genes (APC, BCL2, CCND2, MLH1, PARP1, SLIT2, YES1, XRCC1) we identified differential protein binding from a nuclear extract between the SNP alleles. The screening process allowed us to zoom in from 160 candidate genes to eight genes that may contain functional rSNPs in their promoter regions.


Subject(s)
Allelic Imbalance , Drug Resistance, Neoplasm/genetics , Genes, Neoplasm , Polymorphism, Single Nucleotide , Promoter Regions, Genetic , Cell Line, Tumor , Computational Biology , Electrophoretic Mobility Shift Assay , Gene Expression Profiling , Gene Expression Regulation, Neoplastic , Humans , Sequence Analysis, DNA , Transcription Factors/metabolism
2.
Int J Cancer ; 120(1): 189-95, 2007 Jan 01.
Article in English | MEDLINE | ID: mdl-17072862

ABSTRACT

The myeloma cell line RPMI 8226/S and its doxorubicin resistant subline 8226/Dox40 were used as models to explore the potential importance of the STAT1 signaling pathway in drug and radiation resistance. The 40-fold doxorubicin resistant subline 8226/Dox40 was found to be crossresistant to single doses of 4 and 8 Gy of radiation. A genome-wide mRNA expression study comparing the 8226/Dox40 cell line to its parental line was performed to identify the underlying molecular mechanisms. Seventeen of the top 50 overexpressed genes have previously been implicated in the STAT1 signaling pathway. STAT1 was over expressed both at the mRNA and protein level. Moreover, analyses of nuclear extracts showed higher abundance of phosphorylated STAT1 (Tyr 701) in the resistant subline. Preexposure of the crossresistant cells to the STAT1 inhibiting drug fludarabine reduced expression of overexpressed genes and enhanced the effects of both doxorubicin and radiation. These results show that resistance to doxorubicin and radiation is associated with increased STAT1 signaling and can be modulated by fludarabine. The data support further development of therapies combining fludarabine and radiation.


Subject(s)
Antibiotics, Antineoplastic/therapeutic use , Doxorubicin/therapeutic use , Drug Resistance, Neoplasm , Multiple Myeloma/metabolism , Radiation Tolerance , STAT1 Transcription Factor/metabolism , Antineoplastic Agents/pharmacology , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Blotting, Western , Cross Reactions , DNA (Cytosine-5-)-Methyltransferases/antagonists & inhibitors , Dose-Response Relationship, Radiation , Flow Cytometry , Gamma Rays , Gene Expression Profiling , Humans , Multiple Myeloma/drug therapy , Multiple Myeloma/pathology , Oligonucleotide Array Sequence Analysis , Reverse Transcriptase Polymerase Chain Reaction , STAT1 Transcription Factor/genetics , Signal Transduction/drug effects , Signal Transduction/radiation effects , Tumor Cells, Cultured , Vidarabine/analogs & derivatives , Vidarabine/pharmacology
3.
J Biomol Screen ; 11(5): 457-68, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16928983

ABSTRACT

The squamous cell carcinoma HeLa cell line and an epithelial cell line hTERT-RPE with a nonmalignant phenotype were interrogated for HeLa cell selectivity in response to 1267 annotated compounds representing 56 pharmacological classes. Selective cytotoxic activity was observed for 14 of these compounds dominated by cyclic adenosine monophosphate (cAMP) selective phosphodiesterase (PDE) inhibitors, which tended to span a representation of the chemical descriptor space of the library. The PDE inhibitors induced delayed cell death with features compatible with classical apoptosis. The PDE inhibitors were largely inactive when tested against a cell line panel consisting of hematological and nonsquamous epithelial phenotypes. In a genome-wide DNA microarray analysis, PDE3A and PDE2A were found to be significantly increased in HeLa cells compared to the other cell lines. The pathway analysis software PathwayAssist was subsequently used to extract a list of proteins and small molecules retrieved from Medline abstracts associated with the hit compounds. The resulting list consisted of major parts of the cAMP-protein kinase A pathway linking to ERK, P38, and AKT. This molecular network may provide a basis for further exploitation of novel candidate targets for the treatment of squamous cell carcinoma.


Subject(s)
Carcinoma, Squamous Cell/metabolism , Electronic Data Processing/methods , Gene Expression Profiling/methods , Signal Transduction/genetics , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/genetics , Caspases/metabolism , Combinatorial Chemistry Techniques/methods , Drug Evaluation, Preclinical/methods , HeLa Cells , Humans , Models, Biological , Oligonucleotide Array Sequence Analysis , Phenotype , Phosphodiesterase Inhibitors/pharmacology , Phosphoric Diester Hydrolases/metabolism , Pyridazines/pharmacology , Quinazolines , RNA, Messenger/metabolism
4.
Anticancer Drugs ; 17(5): 503-9, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16702806

ABSTRACT

The aim of the present study was to investigate if basal telomerase activity levels may predict sensitivity to cytotoxic drugs in a panel of human esophageal carcinoma cell lines. The TRAPeze telomerase detection assay was used to investigate telomerase activity in the cell lines. Cytotoxic drug sensitivity for 20 standard cytotoxic agents was assessed using the fluorometric microculture cytotoxicity assay (FMCA). Telomerase activity was detected in all cell lines with a broad range of activity levels. Drug sensitivity also varied considerably between the cell lines. Except for a P value towards a correlation between mitoxantrone and telomerase activity (P=0.054), no statistically significant correlation was found between telomerase activity levels and sensitivity to investigated drugs, including key drugs such as cisplatin (P=0.9), 5-fluorouracil (P=0.8) and doxorubicin (P=0.54). We therefore conclude that basal telomerase activity level is not a key determinant of sensitivity to standard cytotoxic drugs in esophageal carcinoma cell lines.


Subject(s)
Antineoplastic Agents/pharmacology , Cytotoxins/pharmacology , Esophageal Neoplasms , Telomerase/analysis , Biomarkers, Tumor , Cell Line, Tumor , Drug Screening Assays, Antitumor , Enzyme Activation/drug effects , Esophageal Neoplasms/drug therapy , Esophageal Neoplasms/enzymology , Humans , Predictive Value of Tests
5.
Biochem Biophys Res Commun ; 342(4): 1211-7, 2006 Apr 21.
Article in English | MEDLINE | ID: mdl-16516153

ABSTRACT

We have investigated p53-related differences in cellular response to DNA damaging agents, focusing on p53s effects on RAD51 protein level and sub-cellular localization post exposure to ionizing radiation. In a human colon cancer cell line, HCT116 and its isogenic p53-/- subcell line we show here p53-independent RAD51 foci formation but interestingly the resolution of RAD51 foci showed clear p53 dependence. In p53 wt cells, but not in p53-/- cells, RAD51 protein level decreased 48 h post irradiation and fluorescence immunostaining showed resolution of RAD51 foci and relocalization of RAD51 to nucleoli at time points corresponding to the decrease in RAD51 protein level. Both cell lines rejoined DNA double strand breaks efficiently with similar kinetics and p53 status did not influence sensitivity to DNA damaging agents. We suggest that p53 has a role in RAD51 clearance post DSB repair and that nucleoli might be sites of RAD51 protein degradation.


Subject(s)
Colonic Neoplasms/metabolism , DNA Damage , DNA Repair , Rad51 Recombinase/metabolism , Radiation, Ionizing , Tumor Suppressor Protein p53/metabolism , Cell Line, Tumor , Dose-Response Relationship, Radiation , Humans , Radiation Dosage
6.
Cancer Chemother Pharmacol ; 55(1): 47-54, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15565443

ABSTRACT

BACKGROUND: The paclitaxel formulation, Taxol (Bristol-Myers Squibb), is one of the most effective anticancer agents used today. However; it is associated with serious side effects believed to be caused by the Cremophor EL used for its formulation. AIM: To evaluate the cytotoxic activity of a new paclitaxel formulation, Pacliex (developed by Oasmia Pharmaceutical, Uppsala, Sweden), a mixed micelles preparation in which an amphiphilic synthetic derivative of retinoic acid replaced Cremophor EL/ethanol vehicle. METHOD: In this study, three model systems were used to evaluate the cytotoxic activity of Pacliex and other paclitaxel preparations. The cytotoxic activities of Pacliex, Taxol and paclitaxel in ethanol were investigated against a panel of ten human tumor cell lines using the fluorometric microculture cytotoxicity assay (FMCA). Low- and high- proliferating in vitro hollow fiber model of two cell lines, the leukemia CCRF-CEM and the myeloma RPMI 8226/S cell lines, were used to assess the cytotoxic activity of the three formulations. The in vivo hollow fiber model of the two cell lines was used for assessment of Pacliex and Taxol activity. The [3-4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay was utilized to analyze the in vitro and in vivo hollow fiber data. RESULT: Pacliex was somewhat more effective than Taxol in the more sensitive cell lines. The activity of Taxol was more pronounced in the resistant cell lines due to an additive effect of the vehicle used. The three formulations showed similar activity in both the low- and high-proliferating in vitro hollow fiber cultures. The in vivo hollow fiber cytotoxic activity of Pacliex was similar to that of Taxol. Putting all the results together, it was found that all the three formulations had similar in vitro and in vivo activity. CONCLUSION: The three in vitro and in vivo models confirmed the similarity of the cytotoxic activities of Pacliex and Taxol. Considering the above, Pacliex could be an interesting alternative Cremophor EL-free formulation of paclitaxel.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Antineoplastic Agents, Phytogenic/toxicity , Paclitaxel/analogs & derivatives , Paclitaxel/pharmacology , Paclitaxel/toxicity , Chemistry, Pharmaceutical , Humans , Leukemia/pathology , Micelles , Multiple Myeloma/pathology , Tumor Cells, Cultured
7.
Ann Neurol ; 56(3): 342-50, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15349861

ABSTRACT

We describe the ninth variant of neuronal ceroid lipofuscinosis (NCL) or Batten disease, due to defects in a putative new gene, CLN9. We therefore refer to the new variant as CLN9-deficient. Two Serbian sisters and two German brothers are described. Their clinical history is characteristic for juvenile NCL. They show similar gene expression patterns. The existence of this variant is supported by the presence of curvilinear inclusions, fingerprint profiles, and granular osmiophilic deposits in neurons, lymphocytes, and conjunctival cells. Enzyme screening and sequencing of the coding regions of other NCL genes was negative. CLN9-deficient cells have a distinctive phenotype. They have rounded cell bodies, have prominent nucleoli, attach poorly to the culture dish, and are sensitive to apoptosis but have increased growth rates. Gene expression of proteins involved in cell adhesion and apoptosis is altered in these cells. Sphingolipid metabolism is also perturbed. They have decreased levels of ceramide, sphingomyelin, lactosylceramide, ceramide trihexoside, and globoside and increased activity of serine palmitoyl transferase.


Subject(s)
Apoptosis/genetics , Fibroblasts/metabolism , Fibroblasts/pathology , Genetic Variation/genetics , Membrane Proteins/genetics , Neuronal Ceroid-Lipofuscinoses/genetics , Neuronal Ceroid-Lipofuscinoses/pathology , Adolescent , Adult , Cell Adhesion/genetics , Cell Line , Child , Child, Preschool , Female , Genotype , Humans , Male , Membrane Proteins/deficiency , Neuronal Ceroid-Lipofuscinoses/diagnosis , Oligonucleotide Array Sequence Analysis
8.
Anticancer Drugs ; 15(1): 45-54, 2004 Jan.
Article in English | MEDLINE | ID: mdl-15090743

ABSTRACT

The cyanoguanidine CHS 828 has shown promising antitumor properties and is currently in early clinical trials, although the mechanism of action still is largely unknown. In this study, resistant sublines of the histiocytic lymphoma cell line U-937 GTB and the myeloma line RPMI 8226 were developed by culturing under gradually increasing concentrations of CHS 828 until reaching 25 times the parental line EC50s. The new phenotypes demonstrate more than 400-fold resistance to CHS 828 and cross-resistance to six cyanoguanidine analogs, but no resistance to nine standard drugs of different mechanistic classes or to the cytotoxic guanidines m-iodobenzylguanidine and methylglyoxal-bis(guanylhydrazone). The resistant phenotypes were stable for several months even if cultivated in drug-free medium and no difference in proliferation, ultrastructural or morphologic appearance in the sublines could be detected. Neither was decreased accumulation of tritium-labeled CHS 828 observed. Furthermore, the new U-937 phenotype was not accompanied by changes in differentiation or an altered cell-cycle distribution. In the myeloma cell line, esterase activity was shown to be moderately enhanced. Two-dimensional protein electrophoresis was undertaken to unmask possible resistance-mediating proteins and/or the target molecule(s) for CHS 828. In the myeloma cell line, lambda light chain immunoglobulin (down-regulated) and a fatty acid-binding protein (up-regulated) were identified. The findings presented here indicate that development of specific cellular alterations is responsible for the gained CHS 828 resistance.


Subject(s)
Antineoplastic Agents/pharmacology , Cell Line, Tumor/drug effects , Cyanides/pharmacology , Drug Resistance, Neoplasm/drug effects , Guanidines/pharmacology , Antineoplastic Agents/therapeutic use , Cell Cycle/drug effects , Cell Line, Tumor/cytology , Cell Line, Tumor/ultrastructure , Cell Survival/drug effects , Cyanides/therapeutic use , Drug Resistance, Neoplasm/genetics , Drug Screening Assays, Antitumor , Electrophoresis, Gel, Two-Dimensional , Guanidines/therapeutic use , Humans , Lymphoma, Large B-Cell, Diffuse , Microscopy, Electron , Multiple Myeloma , Phenotype , Tritium
9.
Anticancer Drugs ; 14(8): 617-24, 2003 Sep.
Article in English | MEDLINE | ID: mdl-14501383

ABSTRACT

Peptichemio, a mixture of six short oligopeptides all comprising the alkylating amino acid m-L-sarcolysin, has shown clinical activity in several malignancies. Previous studies have suggested that activity mainly resides in one of the peptides, P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester). In the present study the in vitro activity of P2 was further investigated and compared to melphalan and the novel alkylating dipeptide J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester), which is structurally related to P2 and melphalan. Cytotoxic activity was studied using patient tumor cells in a non-clonogenic cytotoxicity assay, whereas cellular response, and kinetics thereof, were studied in the lymphoma cell line U-937 GTB. Cellular metabolism was studied using microphysiometry, kinetic effects on macromolecular synthesis by radiolabeled substrate incorporation and, finally, the microculture kinetic assay of apoptosis was used to monitor morphologic changes following drug exposure. The assays compared P2 favorably with melphalan. Interestingly J1 was even more cytotoxic, and produced more pronounced effects in the kinetic assays for macromolecular synthesis, metabolic activity and apoptosis. The results indicate that the delivery properties of J1 are improved compared to those of melphalan and P2.


Subject(s)
Antineoplastic Agents, Alkylating/pharmacology , Melphalan/analogs & derivatives , Melphalan/pharmacology , Oligopeptides/pharmacology , Antineoplastic Agents, Alkylating/metabolism , Apoptosis/drug effects , Dipeptides , Drug Screening Assays, Antitumor , Humans , Melphalan/metabolism , Oligopeptides/metabolism , Tumor Cells, Cultured
10.
Ann Neurol ; 51(4): 448-66, 2002 Apr.
Article in English | MEDLINE | ID: mdl-11921051

ABSTRACT

Multiple gene defects cause Batten disease. Accelerated apoptosis accounts for neurodegeneration in the late infantile and juvenile forms that are due to defects in the CLN3 and CLN2 genes. Extensive neuronal death is seen in CLN2- and CLN3-deficient human brain as well as in CLN6-deficient sheep brain and retina. When neurons in late infantile and juvenile brain survive, they manage to do so by upregulating the neuroprotective molecule Bcl-2. The CLN3 gene has antiapoptotic properties at the molecular level. We show that the CLN2 gene is neuroprotective: it enhances growth of NT2 cells and maintains survival of human postmitotic hNT neurons. Conversely, blocking CLN3 or CLN2 expression in hNT neurons with adenoviral antisense-CLN3 or antisense-CLN2-AAV2 constructs causes apoptosis. The drug flupirtine is a triaminopyridine derivative that acts as a nonopioid analgesic. Flupirtine upregulates Bcl-2, increases glutathione levels, activates an inwardly rectifying potassium channel, and delays loss of intermitochondrial membrane calcium retention capacity. We show that flupirtine aborts etoposide-induced apoptosis in CLN1-, CLN2-, CLN3-, and CLN6-deficient as well as normal lymphoblasts. Flupirtine also prevents the death of CLN3- and CLN2-deficient postmitotic hNT neurons at the mitochondrial level. We show that a mechanism of neuroprotection exerted by flupirtine involves complete functional antagonism of N-methyl-D-aspartate or N-methyl-D-aspartate-induced neuronal apoptosis. Flupirtine may be useful as a drug capable of halting the progression of neurodegenerative diseases caused by dysregulated apoptosis.


Subject(s)
Aminopyridines/pharmacology , Apoptosis/drug effects , Membrane Glycoproteins , Molecular Chaperones , Neuronal Ceroid-Lipofuscinoses/drug therapy , Neurons/cytology , Neuroprotective Agents/pharmacology , Peptide Hydrolases/genetics , Aminopeptidases , Cell Division/drug effects , Dipeptidyl-Peptidases and Tripeptidyl-Peptidases , Endopeptidases , Gene Expression , Humans , In Situ Nick-End Labeling , In Vitro Techniques , Lymphocytes/cytology , Lymphocytes/drug effects , Membrane Proteins/genetics , Mitosis , Neuronal Ceroid-Lipofuscinoses/genetics , Neuronal Ceroid-Lipofuscinoses/pathology , Neurons/drug effects , Neurons/physiology , Proteins/genetics , RNA, Messenger/analysis , Serine Proteases , Teratocarcinoma , Thiolester Hydrolases , Transfection , Tripeptidyl-Peptidase 1 , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...